Alton Gregg H 4

What Happened
Alton H. Gregg, a director of Corcept Therapeutics Inc. (CORT), was granted a derivative award of 12,500 shares on May 21, 2026. The award was reported on Form 4 as having an acquisition price of $0.00 (i.e., a grant/award rather than a market purchase). This is a grant (not a sale) and should be viewed as an issuance of equity-linked compensation rather than an open-market purchase.

Key Details

• Transaction date: May 21, 2026; Form 4 filed: May 26, 2026 (timely filed within required business days).
• Transaction type: A (Award/Grant of derivative security).
• Shares/units granted: 12,500; price reported: $0.00 (no cash paid by the insider).
• Vesting: Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over one year, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Remarks: Form signed under a power of attorney on file with the SEC.

Context
This is a routine equity award to an insider (director). It represents compensation or incentive tied to continued service and vests monthly over 12 months. Because it is a grant (derivative award) reported at $0, it does not reflect an open-market purchase or sale and does not indicate immediate selling activity.